Next-generation prognostic assessment for diffuse large B-cell lymphoma

Ashley D. Staton, Jean L. Koff, Qiushi Chen, Turgay Ayer, Christopher R. Flowers

Research output: Contribution to journalArticle

1 Scopus citations


Current standard of care therapy for diffuse large B-cell lymphoma (DLBCL) cures a majority of patients with additional benefit in salvage therapy and autologous stem cell transplant for patients who relapse. The next generation of prognostic models for DLBCL aims to more accurately stratify patients for novel therapies and risk-adapted treatment strategies. This review discusses the significance of host genetic and tumor genomic alterations seen in DLBCL, clinical and epidemiologic factors, and how each can be integrated into risk stratification algorithms. In the future, treatment prediction and prognostic model development and subsequent validation will require data from a large number of DLBCL patients to establish sufficient statistical power to correctly predict outcome. Novel modeling approaches can augment these efforts.

Original languageEnglish (US)
Pages (from-to)2443-2457
Number of pages15
JournalFuture Oncology
Issue number17
StatePublished - Sep 1 2015


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this